Alloplex Biotherapeutics on Thursday said it will submit an investigational new drug application to the US Food and Drug Administration to begin a Phase II trial of its autologous peripheral blood mononuclear cell (PBMC)-derived cellular therapy, Suplexa, with immune checkpoint inhibitors in certain colorectal cancers.
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
